High Concentration of Serum Soluble Fas in Patients with Head and Neck Carcinoma: A Comparative Study Before and After Surgical Removal of Tumor
Background:Alternative splicing of the Fas transcript can produce a naturalsecreted isoform of this molecule. Some cancer cells can also produce soluble Fas (sFas)which may have suppressive effects on the immune system's anti-tumor response.Elevated concentrations of sFas have been detected in...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Shiraz University of Medical Sciences
2010-01-01
|
Series: | Middle East Journal of Cancer |
Subjects: | |
Online Access: | http://mejc.sums.ac.ir/index.php/mejc/article/view/5/14 |
Summary: | Background:Alternative splicing of the Fas transcript can produce a naturalsecreted isoform of this molecule. Some cancer cells can also produce soluble Fas (sFas)which may have suppressive effects on the immune system's anti-tumor response.Elevated concentrations of sFas have been detected in the sera of patients with differentmalignancies. Materials and Methods:The concentrations of sFas in sera of patients with headand neck carcinoma (HNC, n=98) and healthy individuals (n=30) were measured bySandwich ELISAand compared to values obtained six months after surgical removalof the tumor (n=48). Data were correlated with different clinical findings of thepatients. Results:sFas concentrations in the sera of HNC patients were found to besignificantly higher in patients with different tumor stages. sFas concentration did notcorrelate with age or tumor invasiveness, however a higher concentration of sFas wasfound in the sera of patients who had higher tumor grades. Surgical removal oftumors in patients resulted in a substantial decrease in sFas concentration.Conclusion:The initial rise in sFas concentration in the sera of HNC patients andits consequent decrease could be regarded as a sign of tumor suppressive mechanisms.Additional studies are needed to fully elucidate this mechanism however these findingsmight show the prospective use of such biomarkers to determine disease prognosis andeven immunotherapeutic applications. |
---|---|
ISSN: | 2008-6709 2008-6687 |